Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease

SARS-CoV-2 is the causative agent of COVID-19. The main viral protease (M(pro)) is an attractive target for antivirals. The clinically approved drug nirmatrelvir and the clinical candidate ensitrelvir have so far showed great potential for treatment of viral infection. However, the broad use of anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Noske, Gabriela Dias, de Souza Silva, Ellen, de Godoy, Mariana Ortiz, Dolci, Isabela, Fernandes, Rafaela Sachetto, Guido, Rafael Victório Carvalho, Sjö, Peter, Oliva, Glaucius, Godoy, Andre Schutzer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2023
Materias:
JBC Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916189/
https://www.ncbi.nlm.nih.gov/pubmed/36775130
http://dx.doi.org/10.1016/j.jbc.2023.103004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916189/
https://www.ncbi.nlm.nih.gov/pubmed/36775130
http://dx.doi.org/10.1016/j.jbc.2023.103004

Ejemplares similares